The advancement in technology has greatly helped the healthcare sector through innovative devices and constant research to develop benefit the healthcare sector. In recent medical research have identified the key factors causing sickle cell disease. The research has found out the proteins that regulate hemoglobin production in red blood cells, thus innovative drugs can targeting hemoglobin to tackle sickle cell disease. This disease is quiet prevalent among the newborns, as the red blood cells transform from a fetal form to an adult form of hemoglobin. Thus, this mutation process causes sickle cell disease among the adults after birth.
The sickle cell disease is life threating, as it forms an abnormal shape and choked blood vessels leading to extreme pain and damaging organs. The researchers are making efforts to improve the treatment facilities, as the drugs used currently are efficient in solving the problem for number of patients. The recent research conducted by Blobel, scientist at Children’s Hospital of Philadelphia and Junwei Shi, PhD. from the University of Pennsylvania, who have focused on a screening tool that uses gene-editing methods from CRISPR. The use of particular screening gadgets, the researchers were able to focus on a class of types incorporating protein kinases or signaling proteins (HRI), where enzymes that can possibly be occupied by a small molecule.
Remarkably, the researchers found ways to reduce the sickling in red blood cells caused due to sickle cell disease without damaging the feasibility or development of the cells while reducing the efficiency of HRI. The study has also found out another blood disorder named beta-thalassemia caused due to abnormal hemoglobin. However, there are other factors causing beta thalassemia that can also be treated through treatment related to HRI.